文献速递泌尿男性生殖肿瘤

OncoLoop:基于网络的精准癌症医学框架

OncoLoop: A Network-Based Precision Cancer Medicine Framework.
PubMed 文献 · Cancer Discov · 2023-01-01

OncoLoop 是一种利用药物扰动谱预测人肿瘤及其预存高保真(同源)模型药物敏感性的精准医学框架。以前列腺癌为概念验证,通过主调节因子(MR)保守性分析将晚期患者与同源基因工程小鼠模型(GEMM)来源肿瘤匹配,预测药物在多种模型中验证成功,并可增强纳武利尤单抗和恩扎卢替胺疗效。

要点

  • OncoLoop 通过药物扰动谱预测人肿瘤及同源模型的药物敏感性。
  • MR 保守性分析显示多数晚期前列腺癌患者有至少一个同源 GEMM 来源肿瘤代表。
  • 预测药物在同种移植、同基因和 PDX 模型中验证成功,并增强纳武利尤单抗和恩扎卢替胺疗效。

核心结论

  • OncoLoop 是一种基于转录组的实验与计算框架,可支持快速转化的共临床研究,为个体患者识别和验证药物,并可随时适应临床实践。
  • 该框架应适用于许多具有合适模型和药物扰动数据的癌症背景。

研究设计与样本

  • 研究引入 OncoLoop 精准医学框架,利用药物扰动谱预测人肿瘤及其预存高保真(同源)模型的药物敏感性。
  • 以前列腺癌为概念验证,使用重现广泛疾病状态(包括去势抵抗性、转移性和神经内分泌前列腺癌)的基因工程小鼠模型(GEMM)。
  • 通过主调节因子(MR)保守性分析 interrogate 人类前列腺癌队列,并在同种移植、同基因和患者来源异种移植(PDX)模型中进行验证。

主要发现

  • MR 保守性分析显示,大多数晚期前列腺癌患者由至少一个同源 GEMM 来源肿瘤(GEMM-DT)代表。
  • 预测可在患者及其同源 GEMM-DT 中逆转 MR 活性的药物,在同种移植、同基因和 PDX 肿瘤及转移模型中均验证成功。
  • OncoLoop 预测的药物增强了临床相关药物 PD-1 抑制剂纳武利尤单抗和 AR 抑制剂恩扎卢替胺的疗效。

临床怎么用

  • OncoLoop 可支持快速转化的共临床研究,为个体患者识别和验证药物,并可随时适应临床实践。
  • 该框架应适用于许多具有合适模型和药物扰动数据的癌症背景。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Prioritizing treatments for individual patients with cancer remains challenging, and performing coclinical studies using patient-derived models in real time is often unfeasible. To circumvent these challenges, we introduce OncoLoop, a precision medicine framework that predicts drug sensitivity in human tumors and their preexisting high-fidelity (cognate) model(s) by leveraging drug perturbation profiles. As a proof of concept, we applied OncoLoop to prostate cancer using genetically engineered mouse models (GEMM) that recapitulate a broad spectrum of disease states, including castration-resistant, metastatic, and neuroendocrine prostate cancer. Interrogation of human prostate cancer cohorts by Master Regulator (MR) conservation analysis revealed that most patients with advanced prostate cancer were represented by at least one cognate GEMM-derived tumor (GEMM-DT). Drugs predicted to invert MR activity in patients and their cognate GEMM-DTs were successfully validated in allograft, syngeneic, and patient-derived xenograft (PDX) models of tumors and metastasis. Furthermore, OncoLoop-predicted drugs enhanced the efficacy of clinically relevant drugs, namely, the PD-1 inhibitor nivolumab and the AR inhibitor enzalutamide. SIGNIFICANCE: OncoLoop is a transcriptomic-based experimental and computational framework that can support rapid-turnaround coclinical studies to identify and validate drugs for individual patients, which can then be readily adapted to clinical practice. This framework should be applicable in many cancer contexts for which appropriate models and drug perturbation data are available. This article is highlighted in the In This Issue feature, p. 247.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Vasciaveo A, Arriaga JM, de Almeida FN, et al. OncoLoop: A Network-Based Precision Cancer Medicine Framework. Cancer Discov. 2023. PMID: 36374194. doi:10.1158/2159-8290.CD-22-0342

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。